CONVERSION TO EVEROLIMUS TO PRESERVE KIDNEY FUNCTION IN A HEART TRANSPLANT RECIPIENT, A PERSONALIZED APPROACH OF IMMUNOSUPPRESSIVE THERAPY

被引：0
作者：
Koloskova, N. N. [1 ]
Nikitina, E. A. [1 ]
Zakharevich, V. M. [1 ,2 ]
Muminov, I. I. [1 ]
Cvan, V. S. [1 ]
Poptsov, V. N. [1 ]
Ahmadzai, R. L. [1 ]
Izotov, D. A. [1 ]
Shevchenko, A. O. [1 ,2 ]
机构：
[1] Minist Healthcare Russian Federat, VI Shumakov Natl Med Res Ctr Transplantol & Artif, Moscow, Russia
[2] Sechenovsky Univ, IM Sechenov Moscow State Med Univ 1, Minist Healthcare Russian Federat, Moscow, Russia
来源：
VESTNIK TRANSPLANTOLOGII I ISKUSSTVENNYH ORGANOV | 2018年 / 20卷 / 03期
关键词：
heart transplanation; immunosuppressive therapy; nephrotoxicity of calcineurin inhibitor; renal dysfunction; everolimus; mTOR inhibitor;
D O I：
10.15825/1995-1191-2018-3-70-74
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
Heart transplantation is the gold standard of treatment severe heart failure. Patient survival after heart transplantation has improved dramatically since the availability of calcineurin inhibitor (CNIs). However, nephrotoxicity of CNIs has been largely responsible for the progressive development of renal dysfunction and reduces long-term patient survival. Use mTOR inhibitor in immunosuppressive therapy may improve renal function when everolirnus is administered associated with a progressive reduction of CNIs. The purpose of our report is to demonstrate the successful case of conversion of the recipient after heart transplatation to evaluate the effectiveness of this drug during the observation year after heart transplantation to ever
引用
收藏
页码：70 / 74
页数：5
相关论文
共 16 条
  • [1] [Anonymous], 2017, JHLT, V36, P1037
  • [2] Recommendations for use of everolimus after heart transplantation: Results from a Latin-American Consensus Meeting
    Bocchi, E. A.
    Ahualli, L.
    Amuchastegui, M.
    Boullon, F.
    Cerutti, B.
    Colque, R.
    Fernandez, D.
    Fiorelli, A.
    Olaya, P.
    Vulcado, N.
    Perrone, S. V.
    [J]. TRANSPLANTATION PROCEEDINGS, 2006, 38 (03) : 937 - 942
  • [3] Nephrotoxic aspects of cyclosporine
    Cattaneo, D
    Perico, N
    Gaspari, F
    Remuzzi, G
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (02) : 234S - 239S
  • [4] Fiocchi R, 2006, TRAPIANTI, V3, P107
  • [5] Gautier SV, 2011, IMMUNOSUPRESSIYA PRI, P12
  • [6] Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?
    Gonzalez-Vilchez, F.
    Vazquez de Prada, J. A.
    Paniagua, M. J.
    Gomez-Bueno, M.
    Arizon, J. M.
    Almenar, L.
    Roig, E.
    Delgado, J.
    Lambert, L.
    Perez-Villa, F.
    Sanz-Julve, M. L.
    Crespo-Leiro, M.
    Segovia, J.
    Lopez-Granados, A.
    Martinez-Dolz, L.
    Mirabet, S.
    Escribano, P.
    Diaz-Molina, B.
    Farrero, M.
    Blasco, T.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 171 (01) : 15 - 23
  • [7] Two-Year Outcomes in Thoracic Transplant Recipients After Conversion to Everolimus With Reduced Calcineurin Inhibitor Within a Multicenter, Open-Label, Randomized Trial
    Gullestad, Lars
    Mortensen, Svend-Aage
    Eiskjoer, Hans
    Riise, Gerdt C.
    Mared, Lena
    Bjortuft, Oystein
    Ekmehag, Bjorn
    Jansson, Kjell
    Simonsen, Svein
    Gude, Einar
    Rundqvist, Bengt
    Fagertun, Hans E.
    Solbu, Dag
    Iversen, Martin
    [J]. TRANSPLANTATION, 2010, 90 (12) : 1581 - 1589
  • [8] Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial
    Gullestad, Lars
    Iversen, Martin
    Mortensen, Svend-Aage
    Eiskjaer, Hans
    Riise, Gerdt C.
    Mared, Lena
    Bjortuft, Oystein
    Ekmehag, Bjorn
    Jansson, Kjell
    Simonsen, Svein
    Gude, Einar
    Rundqvist, Bengt
    Fagertun, Hans E.
    Solbu, Dag
    Bergh, Claes-Hakan
    [J]. TRANSPLANTATION, 2010, 89 (07) : 864 - 872
  • [9] Recommendations for use of Certican® (everolimus) after heart transplantation:: Results from a German and Austrian consensus conference
    Hummel, M
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (04) : S196 - S200
  • [10] Multicenter Randomized Trial of Everolimus vs. Mycophenolate Mofetil in Heart Transplantation: Final 24 Month Analysis of Efficacy and Safety
    Kobashigawa, J.
    Pauly, D.
    Kfoury, A.
    Ross, H.
    Wang, S-S.
    Cantin, B.
    van Bakel, A.
    Starling, R. C.
    Hirt, S.
    Dong, G.
    Panis, C.
    Lopez, P.
    Eisen, H.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04) : S75 - S75
12